Novartis AG

NVSNYSE • USD
ThemeHealthcare - Oncology›Targeted Therapy & Precision Oncology
152.73 USD
↗ 1.93 (1.28%)AT CLOSE (11:59 AM EDT)
152.22
↘ 0.51 (0.33%)
POST MARKET (AS OF 07:44 PM EDT)
Post Market
AS OF 07:44 PM EDT
152.22
↘ 0.51 (0.33%)
🔴Market: CLOSED

NVS is currently priced at $152.75. The technical outlook is "Neutral" and the fundamental picture shows "Neutral". This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 0/9 and a bullish Golden Cross on the moving averages. On the valuation front, NVS trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.

Technical & fundamental data as of Jul 16, 2026.

Open?$150.48
High?$153.18
Low?$150.21
Prev. Close?$150.80
Volume?2.4M
Avg. Volume?2.1M
VWAP?$152.30
Rel. Volume?1.11x
Bid / Ask
Bid?$126.80 × 100
Ask?$157.00 × 100
Spread?$30.20
Midpoint?$141.90
Valuation & Ratios
Market Cap?287.7B
Shares Out?2.0B
P/E Ratio?59.10
P/B Ratio?3.84
EPS?$2.55
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
Themes
Healthcare - Oncology›Targeted Therapy & Precision OncologyBiotech - Drug Development›Immunology & Autoimmune
Employees
75.3K
Market Cap
287.7B
Industry
N/A
Website
www.novartis.com
Listed
1996-11-07
Technical OutlookNeutral
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
98
Momentum?
50
Short Sent.?
66
Piotroski F-Score?0/9Weak
Altman Z-Score?4.88Safe
Confidence?45%Low
Full Fundamental Analysis →
Short InterestLow
Short Interest?5.4M
Days to Cover?2.0
Avg Daily Volume2.7M
Settlement Date2026-06-30
Financial Health
Current Ratio?1.12Adequate
Quick Ratio?0.84Weak
Cash Ratio?0.35Low
Debt/Equity?0.24Low
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score
40/100
P/E?
Peers
100
S&P
9
59.1PRICEY▾
P/B?
Peers
100
S&P
46
3.84FAIR▾
P/S?
Peers
100
S&P
14
7.72HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
Peers
100
S&P
8
33.7HIGH▾
EV/Sales?
Peers
100
S&P
17
7.99HIGH▾
Returns & Efficiency
ROE?
Peers
50
S&P
22
6.5%FAIR▾
ROA?
Peers
50
S&P
34
3.7%FAIR▾
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$297.9B
Fundamentals ratios updated end of day
MarketsMoversWatchlist